If you have a high tolerance for risk, then Bell Potter thinks it could be worth considering the ASX biotech stock in this article.
In fact, if everything goes to plan, the broker believes this speculative stock could more than double in value over the next 12 months.
Which ASX biotech stock?
The stock in question is Imugene Ltd (ASX: IMU). It is a drug developer specialising in the development of new agents for various cancer indications.
Bell Potter notes that the company has a history of in-licensing early-stage assets, typically pre-clinical or with phase 1 data, and progressing their development.
Consequently, it points out that the risk of failure is probably high, however “the future financial benefit from development of a new chemical entity for the treatment of disease are immense.”
Bell Potter has been speaking to a leading haematological oncologist in relation to the ASX biotech stock’s Azer-cel product. The good news is that the oncologist has spoken positively about its potential. The broker explains:
Our recent discussion with a leading Haematological Oncologist regarding IMU’s Azer-cel has provided significant assurance regarding its potential in the treatment landscape for both common and rare forms of Non Hodgkins Lymphoma (NHL).
The broker also highlights that recent trial data has been encouraging. It adds:
The CAR-T naïve patient group continues to enrol and early signs of efficacy are highly encouraging. Hi[gh] risk Mantle Cell Lymphoma patients typically fail quickly on first and second line therapies including BTKi. These patients are particularly well suited to Azer-cel where healthier donor T-cells provide potentially superior in vivo expansion versus patient-derived cells in this setting. The company continues to enrol patients in this cohort where the off the shelf solution remains a major attraction of oncologists who otherwise have few treatment options.
Big potential returns
According to the note, the broker has retained its speculative buy rating and 25 cents price target on the ASX biotech stock.
Based on its current share price of 9.3 cents, this implies potential upside of almost 170%.
Commenting on its recommendation, Bell Potter said:
Azer-cel remains an outstanding alternative for the treatment of NHL. The next catalyst is the median DoR data in the DLBCL population (n=17) and further interim data from the CAR-T naïve group and BTKi concurrent combination. Valuation and earnings are unchanged.
The post Guess which ASX biotech stock could rise over 150% appeared first on The Motley Fool Australia.
Should you invest $1,000 in Imugene right now?
Before you buy Imugene shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- These two ASX financial services companies could both jump more than 50% Shaw and Partners says
- Down 30%: Is this ASX 200 stock a buy after its crash?
- This ASX tech stock has exploded 75% in a month, but can it climb higher?
- This ASX mining stock tipped to rise 50% could make a profit of $250m in 2028
- The average superannuation balance at age 53 in Australia, versus what you need to retire comfortably
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.